

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a "t" indicate tables.

- Abdominal aorta, 105
Abdominal muscles, 133, 155
Acid phosphatase, 120t
Activella (estradiol/norethindrone acetate), 214t, 220
Activities of daily living, 316-317
Actonel. *See Risedronate.*
Adjustive hormone therapy, 207-211, 209, 210t, 235t
Adolescence
 bone mass in, 21, 24, 59, 61
 bone remodeling in, 21, 22-23
 bone strength index in, 24
 calcium intake, recommended, 173t
 exercise in, 37
 IGF and SHBG systems in, 41
 nutrition in, 37
Adrenal function tests, 111
Adrenocortical overactivity, 48, 60t
Adulthood, early. *See also Adolescence.*
 bone remodeling in, 21, 22-23
 calcium intake in, 36
Aerobic exercise, 156-157
Age/aging. *See also Elderly persons.*
 bone loss and, 19, 38, 87, 323
 bone wear and tear in, 14
 gender and, 19, 22-23
 bone mass and, 34-35, 38, 87
 accrual of, 14, 21, 22-24, 34-35
 bone remodeling and, 20-21, 22-23
 calcium intake and, 161-162, 163, 173t
 central nervous system and, 56-57
 DEXA reference values, 85
 fractures, average age for, 47, 105
 hip fracture prediction and, 68
 muscle loss and, 149-150
 as osteoporosis risk factor, 65
 osteoporosis screening and, 64, 65, 90-92
 parathyroid hormone concentration and, 57
 sarcopenia and, 149-150
 trabecular structural changes and, 25
 vitamin D intake and, 183
Alcohol intake
 bone loss and, 59, 125
 evaluation of, 125
 falls, risk of, 59
 osteoporosis risk/screening and, 59, 64, 68
Alendronate (Fosamax), 244t, 251-258
 action mechanisms, 249-250
 chemical structure, 251
 clinical trials, 253, 254-255
 discontinuation of treatment, 253
 dosage, 244t, 252-253, 257-258
 effectiveness, 251
 bone mineral density, 253, 254-255
 fracture risk reduction, 244t, 252
 vs ibandronate, 266, 267
 vs risedronate, 253, 254-255
 hormone therapy combined with, 257
 hormone therapy vs, 256-257
 indications for, 244t, 252
 previous fracture and, 253-256
 side effects, 244t, 257
Alendronate/cholecalciferol (Fosamax Plus D), 244t, 258
Alkaline phosphatase
 as bone formation biomarker, 115-116, 120t
 bone-specific, 115-116, 120t, 309, 310, 311-312
 monitoring during estrogen therapy, 218
 in osteopenia screening, 64, 65
Alora (transdermal estradiol), 210, 212t
Aluminum-containing antacids, 48, 60t, 124, 176t
Amenorrhea
 bone mass and, 61-62, 153
 calcium requirements in, 153, 176t
 exercise-induced, 37, 60t, 61-62, 152
 estrogen therapy and, 217
 monitoring of, 62
American Association of Clinical Endocrinology (AACE)
 osteoporosis screening recommendation, 90
 prevention and treatment recommendations, 70t-71t
AMG 162. *See Denosumab.*
Anabolic agents, 16
Anabolic effect of PTH, 301-302
Androgen therapy, 222-229. *See also Androgens; Hormone therapy.*
 action mechanisms, 223-226, 309
 bone loss/bone mass and, 222
 dosage, 214t-215t, 226-228
 minimal effective dose, 309
 effectiveness, 308-309, 310-312, 311-312
 estrogen/androgen therapy, 43, 214t-215t, 222-223, 308-309, 310-312
 exercise and, 27, 150
 formulations, 214t-215t, 226-228
 indications for, 223, 228, 308-309
 lean tissue mass and strength and, 226, 227t
 mechanical loading and, 30
 monitoring, 228-229
 muscle strength and, 226, 227t
 regimens, 226-228
 safety/side effects, 228-229

- Androgens, 43, 308-309. See also *Androgen therapy*.
 age-related decrease in, 324
 deprivation therapy for prostate cancer, 324
 estrogen synthesis from, 42, 43, 206, 223
 levels in women, by menopausal status, 225t
 receptors in osteoblasts and osteoclasts, 26
- Android (methyltestosterone), 214t
- Androstenedione, 42, 223, 224
 level in women, by menopausal status, 225t
- Angeliq (drospirenone/estradiol), 214t
- Angina, 233
- Anorexia nervosa
 bone mass and, 37, 62-63
 calcium intake needs, 176t
- Anovulation, bone mass and, 38, 42, 61
- Antacids with aluminum, 48, 60t, 124, 176t
- Anticonvulsants, 48, 60t
- Antidepressants, tricyclic, 123-124
- Antiepileptic drugs, 324
- Antipsychotics, 123-124
- Antiresorptive agents, 243-300. See also *specific drug classes and agents*.
 action mechanisms, 247-250
 anticipated clinical outcomes, 246-249, 246, 248
 approved agents, 244t-245t
 drug classes, 243
 bisphosphonates, 249-276
 calcitonin, 281-285
 other drugs, 285-289
 selective estrogen receptor modulators, 276-280
 effectiveness, 246-249
 indications for, 70t-71t, 243
 selection among, 289-290
- Appendicular skeleton, 17, 18
- Aromatase, 223, 224
- Arthritis, 22
- Ascorbic acid (vitamin C), 193-194
- Asthma, 217, 222, 324
- Atherosclerosis, 232, 234
- Athletes
 amenorrhea in, 61-62, 152, 154
 bone mass in, 62, 151, 158
- Axial skeleton, 17, 18
- Aygestin (norethindrone acetate), 213t
- Back muscles, 130-134, 155
- Back pain, 130-133. See also *Pain*.
 causes of
 leg length disparity, 133, 137
 for lower back, 132-133, 136-137
 paravertebral muscle spasm, 132, 136
 for upper back, 130-132, 134-135
- Balance. See also *Falls*.
 in bone remodeling, 33-34, 34
 falls and, 134-139, 142t, 149
 leg length disparity and, 138-139
 physical therapy and, 316
 whole body vibration and, 152
- Barbiturates, 123
- Benign positional vertigo, 142t
- Beta carotene, 194
- BGP (bone GLA-protein). See *Osteocalcin*.
- Biceps, 152, 155
- Biconcave deformity, 104
- Biochemical markers, 115-121, 120t
 of bone formation, 32-33, 115-117, 120t
 of bone mass, 41
 of bone resorption, 117-121, 120t
 clinical use of, 119-121, 302, 309
- Biomarkers. See *Biochemical markers*.
- Bisphosphonates, 249-276. See also *Antiresorptive agents; specific agents*.
 action mechanisms, 249-250
 chemical structures, 251
 in children, 276
 drugs available, 244t, 251-274
 effectiveness, 251
 osteoclast functions and, 26
 osteonecrosis of the jaw and, 275-276
 pharmacology, 249-251
 with previous fracture, 253-256
 third generation, 250, 263-274
- BMD (bone mineral density). See *Bone mass*.
- Body composition and frame, 125-127, 126t, 128t-130t
- Body fat. See also *Obesity*.
 androgen therapy and, 226
 low, as indication for estrogen therapy, 217
 percentage of, 125
 as source of estrogen, 42
- Body mass index
 determination of, 125-127
 osteoporosis risk and, 68
 table of, 128t-129t
- Body mechanics, 315-317
- Body protein reserves, muscle mass and, 127
- Body weight, 125-127, 128t-129t. See also *Eating disorders; Obesity*.
 DEXA reference values and, 86
 ideal, by height and frame size, 127t
- Bone, 17-45. See also *Cortical bone; Trabecular bone; and other bone entries*.
 blood supply, 21
 cells. See *Osteoblasts; Osteoclasts; Osteocytes*.
 compartments of skeleton, 17-19, 18
 envelopes/surfaces, 20, 20

Bone (*continued*)

- fragility, 13-14, 56
- geometry, 14, 21
- Haversian system in, 20, 21
- microarchitecture, 20, 25, 49-50, 50
- antiresorptive agents and, 247, 248
 - fracture risk and, 203
 - quantification of damage to, 109-110, 110, 311
- structural anatomy, 19-24
- structural characterization of, 78
- tensile strength of, 32. See also *Bone strength*.
- types of, 17-19
 - variable region, 17
 - wear and tear of, 14
- BONE (Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe), 263-264
- Bone balance, 33-34, 34
- Bone densitometry. See also *Bone mass measurement*.
 - cost of, 77, 79t, 80
 - indications for, 77t
 - interpretation of, 51-53, 80-87
 - normal values in, 74-77, 77t
 - repeated, 80, 89
 - T-score and Z-score in, 74-76, 85
 - techniques in, 79t
 - two- vs three-component, 96-97, 97
- Bone formation, 30-31, 32-33. See also *Bone remodeling*.
 - age and gender in, 20-21, 22-23
 - androgens and, 309, 310
 - biochemical markers of, 32-33, 115-117, 120t, 309, 310
 - calcium and, 161
 - collagen in, 32-33
 - endocrine factors in, 30-31, 38-43
 - exercise and, 149, 153, 156
 - inadequate. See *Osteopenia*.
 - osteocalcin in, 32, 116
 - stimulators of, 30, 243, 247, 301-314. See also *Androgen therapy*;
Parathyroid hormone.
 - vitamin D and, 33, 39-40
- Bone fragility, 13-14
 - hip fracture and, 56
- Bone GLA-protein. See *Osteocalcin*.
- Bone loss, 47-58. See also *Bone remodeling*; *Risk factors for osteoporosis*.
 - alcohol intake and, 59, 125
 - androgens and, 222
 - anovulation and, 38, 42
 - biochemical markers of, 117-121, 120t
 - calcitonin and, 177
 - calcium and, 177
 - chemotherapy-induced, risedronate and, 261
 - in cortical bone, 19

Bone loss (*continued*)

- estrogen and. See *Estrogen*; *Estrogen therapy*.
- fast bone losers, identification of, 74t, 80
- gender and age and, 19, 22-23
- glucocorticoids and, 40-41
- gynecologic factors and, 60-62, 60t
- lactation, extended, and, 62
- parathyroid hormone and, 56, 57
- postmenopausal, 15, 33, 38
- rate, pre- and postmenopausal, 38, 216
- reversible, 49, 50, 52
- thyroid hormones and, 40
- in trabecular bone, 19, 19, 49, 50
- vitamins and, 183, 190t, 191, 194-195
- Bone marrow, 20, 21, 24
- Bone mass, 34-38, 50-53
 - accrual of, 35-38, 36, 324
 - endocrine factors and, 38-43
 - exercise and, 36, 149, 150-154
 - importance of, 14, 15, 34-35
 - in adolescents, 21, 22-24, 61
 - age and, 14, 15, 34-35, 87, 323
 - amenorrhea and, 61-62, 153
 - anabolic agents and, 16
 - antiresorptive agents and, 246-247, 246, 248
 - alendronate, 253, 254-255, 267
 - calcitonin, 282
 - denosumab, 289
 - ibandronate, 264-269, 265, 267
 - raloxifene, 277-278
 - risedronate, 253, 254-255, 259, 261-262
 - strontium ranelate, 287-288
 - in athletes, 62, 151, 158
 - balanced, 33-34, 34
 - bone strength and, 14, 50
 - calcium intake and, 36, 36
 - corticosteroid therapy and, 41
 - dysfunctional menstrual cycles and, 37-38, 38, 60t
 - early assessment of, 14
 - eating disorders and, 37, 60t, 62-63
 - estrogen therapy and, 204, 206, 206, 208, 216
 - combined estrogen/androgen therapy, 309, 311-312
 - ethnicity and, 35
 - exercise and, 21, 36, 37, 149, 150-154
 - factors influencing, 59-72, 60t
 - fracture risk and, 13, 51, 53, 56, 73-76, 75t, 203
 - gynecologic factors in, 60-62, 60t
 - heredity and, 35, 36, 59
 - hormonal status and, 36, 37-38
 - hormone therapy and. See *Hormone therapy*;
specific hormone therapies.
 - lifestyle and, 59, 60t, 324

Bone mass (*continued*)

- measurement of. See *Bone mass measurement*.
- mechanical strength and, 51, 52
- monitoring, 41. See also *Bone mass measurement*.
- normal value, determination of, 76-77
- nutrition and, 36-37, 36
- parathyroid hormone and, 302-304, 304t, 305, 306-307
- peak, 34-35, 76-77
 - age at, 34-35
 - factors influencing, 35-38, 36
 - heredity and, 59
 - importance of, 14, 15, 34-35
 - normal, 76-77, 77t
 - vertebral bone, 38
- race/ethnicity and, 14
- reduced, in osteopenia/osteoporosis, 50-53
- in twins, 59
- vitamin A and, 195
- vitamin C and, 193
- vitamin D and, 35, 37, 190t
- vitamin K and, 191

Bone mass measurement, 73-100

- bone mass and fracture risk, 73-76
- cost of, 77, 79t, 80
- indications for, 74t
- normative values, 74-77, 77t
- osteoporosis screening, 87-92, 93t-95t
 - age at, 90-92
 - osteopenia-identification program, 89
- reference values, 85-86
- structural characterization of whole bone, 78
- technology/techniques, 77-87, 79t
 - dual-energy x-ray absorptiometry (DEXA), 79t, 80-87, 81
 - new technology, 96-97, 97
 - peripheral screening, 88-89
 - quantitative bone ultrasound, 92-96
 - single photon absorptiometry (SPA), 87, 88
 - single x-ray absorptiometry (SXA), 79t, 88, 89
 - three-component densitometry, 96-97, 97

Bone matrix

- constituents/synthesis, 26, 29, 32, 161
- evaluation of, 121

Bone mineral density (BMD). See *Bone mass*.

Bone mineralization, 26, 32-33, 40, 161

Bone remodeling, 24-33, 115-122. See also *Bone formation*;

- Bone resorption*.
 - age and gender in, 20-21, 22-23, 25
 - agents influencing, 33-34, 40
 - antiresorptive agents and, 247-249, 248
 - balance/imbalance in, 33-34, 34, 301, 302
 - biochemical markers of, 115-121, 120t
 - bone envelopes and, 20-21, 22-23

Bone remodeling (*continued*)

- bone formation in, 30-31, 32, 115-117, 120t
 - bone resorption in, 29, 30-31, 117-121, 120t
 - in cortical bone, 17, 20-21, 22-23, 50
 - cycle of, 27-33, 28
 - definition of, 24
 - drugs influencing, 124
 - evaluating, 115-122
 - excessive, 33, 34
 - exercise and, 37, 125, 150-153
 - high-turnover vs low-turnover, 301, 302
 - mechanical loading and, 30
 - osteoblasts in, 33, 34
 - osteoclasts in, 24-26, 33, 34
 - in primary osteoporosis, 47
 - steps in, 27-33, 30-31
 - stimulators of, 30, 243, 247, 301-314
 - tests for status of, 33
 - in trabecular bone, 17, 21, 25
 - trabecular vs cortical, 17
 - uncoupling in, 33, 47
- Bone resorption, 29, 30-31, 33, 34. See also *Antiresorptive agents*;

Bone loss.

- estrogen/androgen therapy and, 310
- markers of, 117-121, 120t

Bone strength

- in adolescents, 24
- bone mass and, 14, 50, 51
- estrogen therapy and, 204
- exercise and, 21
- mechanical, 51, 52
- tensile, 32
- trabecular plates and, 21, 25
- in vertebrae, age and, 25

Boniva. See *Ibandronate*.

Bony landmarks of the back, 132-133

Breast cancer, 229, 230, 232

- chemotherapy-induced bone loss, risedronate and, 261
- risk reduction, raloxifene and, 276-277

Breast examination and mammograms, 219

Broadband ultrasound attenuation (BUA), 94, 96

BSIt (torsional bone strength index), 24

Bulimia, bone mass/osteoporosis risk and, 37, 63

C-carboxyterminal peptide (CTx), 118-119

Caffeine intake, 64, 125

- bone loss and, 59, 125
- calcium intake and, 176t
- as osteoporosis risk factor, 59

Calcaneus

- bone densitometry of, 88, 89
- three-component densitometry, 97, 97
- quantitative ultrasound of, 94-96

Calcineurin inhibitors, 327
Calcitonin, 40, 281-285
 action mechanisms, 40, 281, 283
 available preparations, 245t, 281-283
 bone formation and, 40
 bone loss and, 177
 effectiveness of, 282-283
 estrogen and, 42, 204
 indications for, 245t, 281, 282, 284
 long-term compliance with, 285
 osteoclast inhibition by, 27, 40, 281
 precautions, 284
 regimens, 283-284
 salmon calcitonin, 245t, 281-283
Calcitriol, 286
Calcium, 161-179. See also *Vitamin D*.
 absorption of, 36-37, 124, 162-175
 in elderly women, 124, 163
 estrogen and, 42, 162, 177, 203
 glucocorticoids and, 40
 vitamin D and, 57, 177, 179, 190t
 age and, 161-162, 163
 in bone formation, 33
 bone mass and, 36, 36
 calcium-to-creatinine ratio, 117, 211, 217, 218
 calcium-to-phosphorus ratio, 178-179, 184t-185t
 diuretics and, 178
 diurnal metabolism of, 174
 effectiveness of, 175-178
 estimation/calculation of, 162, 164t-167t, 168-173
 excess, 125
 exercise and, 153
 food sources, calcium content of, 164t-167t
 forms and formulations of, 174, 180t-182t
 risedronate with (Actonel with Calcium), 244t, 263
 homeostasis, skeleton as reservoir for, 17
 intake
 age and, 162, 163
 assessment form, 168-173
 average daily, 162
 deficient, as risk factor for osteoporosis, 59, 60t
 estimation/calculation of, 162, 164t-167t, 168-173
 excess, 125
 guidelines, 124-125
 lactose intolerance and, 57
 recommended daily, 70t, 124, 161-162, 180t-182t
 by age group, 161, 173t
 in amenorrheic women, 153
 with estrogen therapy, 210
 by life stages, 173t
 by menopausal status, 162
 as screening factor, 64
 special needs for, 176t

Calcium (*continued*)
 low-calcium diet, 176t
 proton pump inhibitors and, 174-175
 renal stone formation and, 176t, 178
 supplementary, 162-175, 180t-182t
 absorption from, 163, 174
 bioavailability of, 36, 174
 guidelines for, 124-125, 180t-182t
 indications for, 57, 124
 lifetime exposure to, 176
 lifetime need for, 177
 recommended daily intake, 70t, 124, 161-162, 180t-182t
 side effects of, 178
 timing of, 174, 175
 types of, 174, 180t-182t
 thiazide diuretics and, 117, 124
 urinary excretion, as bone resorption marker, 117, 121
 vitamin D with, necessity for, 57, 177. See also *Vitamin D*.
Caltrate (calcium carbonate), 180t
Cancellous bone. See *Trabecular bone*.
Cancer
 of breast, 229, 230, 232
 chemotherapy, risedronate and, 261
 of colon, 232
 of endometrium, tamoxifen and, 279
 of lung, 230
 metastatic
 secondary osteoporosis from, 48
 zoledronic acid for, 270
 of prostate, 324
Cardiorespiratory fitness, 150, 156-157. See also *Exercise*.
Cardiovascular disease (CVD)
 deaths from, 230
 hormone therapy and, 221, 230-235, 233
 prevention of, timeline for, 233
Cardiovascular fitness, 150, 156-157
Caspase system, bisphosphonates and, 250
Cenestin (synthetic conjugated estrogens), 212t
Center for Climacteric Studies (Gainesville, Florida), 64
Central nervous system
 disorders, falls and, 56-57, 142t
 estrogen and, 204
 raloxifene and, 277
Cerebral ischemia, 135, 142t
Chemotherapy, risedronate and, 261
Children
 bisphosphonate use in, 276
 bone remodeling in, 20, 22-23
 calcium intake, recommended, 173t
 exercise in, 37, 151
 osteoporosis in, 324
Cholecalciferol (vitamin D₃), 181t
 with alendronate (Fosamax Plus D), 244t, 258

- Cholesterol
 androgen therapy and, 228-229
 hypercholesteremia, 73, 194
 progestogen therapy and, 220-221
- Citracal (calcium citrate), 180t
- Climara (transdermal estradiol), 210, 212t
- Climara Pro (transdermal levonorgestrel/estradiol), 215t
- Clinical evaluation, 123-143
 balance, falls, and fractures, 134-139, 142t
 body composition and frame, 125-127, 126t, 128t-130t
 history, 123-125
 muscle strength, 130-134, 134-141
 sample form for, 146-147
 skeleton, 127-130, 131-133
 visual impairment, 139, 148
- Clinical types of osteoporosis, 47-48
- Clodronate, 249, 251, 275
- Cola beverages, phosphorus content of, 178-179
- Collagen
 assays, as bone formation monitor, 32, 32-33, 116
 in bone matrix, 26, 32, 161
 cross-links
 bone mineralization and, 32-33
 bone tensile strength and, 32
 homocysteine and, 183
 urinary excretion of, 41, 118-119, 120t, 211, 217, 218
 gene polymorphisms, bone mass and, 35
 synthesis
 estrogen and, 26, 42, 203
 osteoblasts and, 26, 32
 vitamin C and, 193
- CombiPatch (estradiol/norethindrone acetate), 215t
- Compliance, patient
 bone mass information and, 35
 bone mass measurements, repeated, and, 80
 in hormone therapy, 220, 235t
- Compression deformity, 101, 104
- Computed tomography, quantitative, 79t
- Conjugated equine estrogen (CEE, Premarin), 212t
 alendronate compared with, 256-257
 cardiovascular risks and, 230-231
 dosages, 210, 210t, 211, 212t
 fracture prevention, 203
 parathyroid hormone combined with, 305, 306-307
 pharmacokinetics of, 234
 safety of, 234
- Connective tissue disorders, secondary osteoporosis from, 48
- Coronary arteries, hormone therapy and, 231
- Cortical bone, 19-21
 anatomy of, 19-21, 20
 during puberty, 61
 envelopes/surfaces of, 19-20, 20
- Cortical bone (*continued*)
 loss of, 47, 49-50
 age correlation, 19
 rate of, 38
 vs trabecular bone, 19, 38
 in midshaft radius, 17
 remodeling cycle of, 20-21, 22-23
- Corticosteroids
 bone formation and, 40-41
 bone loss and, 41
 excess, 40
 osteoblast inhibition by, 29
 therapy with
 alendronate and, 257
 hormone therapy and, 22
 osteopenia/osteoporosis induced by, 65, 324, 325-326
 risedronate and, 261
- Cost
 of bone densitometry, 77, 79t, 80
 cost-effectiveness of screening, 15-16
 of osteoporosis-related fractures, 15
- CPY19 (aromatase), 223, 224
- Creatinine, calcium ratio to, 117, 211, 217, 218
- Crinone (progesterone vaginal suppositories), 214t
- Crown-to-rump height, 127-130, 131
- Crush deformity, 104
- CTx (C-carboxytelopeptide), 118-119
- Cyclic adenosine monophosphate (cAMP), 26
- Daily living, activities of, 316-317
- Dehydroepiandrosterone (DHEA), 223, 224
 in androgen/estrogen synthesis and metabolism, 224
 decline in, sarcopenia and, 150
 level in women, by menopausal status, 225t
- Dehydroepiandrosterone sulfate (DHEAS), 223, 225t
- Delatestryl (testosterone enanthate), 214t, 228
- Denosumab, 287, 288-289
- Densitometry. *See Bone densitometry.*
- Dental radiograph, in diagnosis of osteoporosis, 111, 112
- Deoxyypyridinoline (dPyr), assay for, 118, 120t
- Depression, SSRIs in treatment of, 325
- DEXA. *See Dual-energy x-ray absorptiometry (DEXA).*
- DHEA. *See Dehydroepiandrosterone.*
- DHEAS. *See Dehydroepiandrosterone sulfate.*
- Diabetes
 progestogen therapy and, 221
 secondary osteoporosis from, 48, 60t, 326
- Diagnosis of osteoporosis, 101-114. *See also Clinical evaluation.*
 bone densitometry in, 103-104, 105. *See also Bone densitometry.*
 bone mass in, 14, 101. *See also Bone mass measurement.*
 normal bone mass in some patients, 105
 bone remodeling markers not appropriate for, 119

Diagnosis of osteoporosis (*continued*)

- dental radiographs in, 111, 112
- hip fractures in, 105-109
- new technologies in, 109-111, 110
- secondary osteoporosis, 47-48, 111
- vertebral fractures in, 101-105

Didronel. See *Etidronate*.

Diet. See *Nutrition*.

Digital topologic analysis (DTA), 109-110, 110, 311

Dihydrotestosterone, 223

Diuretics, 68

- fracture risk and, 117, 124
- renal stones and, 178

Dizziness

- differentiation of types of, 135, 142t
- as factor in falls, 56, 134-136

Dorsal kyphosis, 103, 130

DPA. See *Dual-energy photon absorptiometry*.

Drospirenone, 214t, 220

Drug therapy. See *Treatment of osteoporosis*.

DTA (digital topologic analysis), 109-110, 110, 311

Dual-energy photon absorptiometry (DPA), 87

Dual-energy x-ray absorptiometry (DEXA), 79t, 80-87, 302, 309

- accuracy and precision of, 79t, 80
- advantages of, 80
- cost of, 79t
- of forearm, 88
- of hip (femoral neck/triangle), 82-85, 85, 105
- indications for, 80, 87, 218
- interpretation of, 80-87, 81
 - conditions interfering with, 105
 - general caveats, 51-53
 - reference values, 83-84, 85-86
- of lumbar spine, 80-82, 81, 83-84
- in osteopenia identification, 51, 89
- patient positioning for, 104
- quality assurance/calibration, 86-87
- radiation dosage from, 79t
- repeated, 80, 89
- of vertebral fracture, 103-104, 105
- vs three-component densitometry, 96-97, 97

DXL Calscan, 97, 97

Eating disorders

- bone mass/osteoporosis risk and, 37, 60t, 62-63
- calcium intake needs, 176t
- vertebral fractures and, 62

Ehlers-Danlos syndrome, 48

Elbow breadth, 127, 130

Elderly persons. See also *Age/aging*.

- bone loss in, 216
- calcium absorption in, 124, 163

Elderly persons (*continued*)

calcium intake, recommended, 161, 173t

depression, SSRIs in treatment of, 325

estrogen therapy for, 217-218

exercise and, 156

falls, risk of, 53-57, 54-56

fractures in, 53-57, 56

diabetes and, 326

lower extremity length as predictor of, 130

risk reduction with diet and exercise, 153

vitamin D intake and, 185, 191

senile secondary hyperparathyroidism in, 48, 57

walking speed and falls in, 53-56, 54-55

Endocrine factors in bone formation/remodeling, 30-31, 38-43

Endocrinopathies, secondary osteoporosis from, 48, 60t, 111

Endometrium

cancer of, tamoxifen and, 279

hyperplasia, estrogen-induced, protective effect of progesterone, 219, 221, 235

monitoring in estrogen therapy, 219

Endosteal envelope, 20, 20

End-plate deformity, 101

Enjuvia (conjugated estrogens), 212t

Equilibrium. See *Balance*; *Dizziness*.

Ergocalciferol (vitamin D₂), 181t

Esterified estrogens/methyltestosterone (Estratest, Estratest H.S.), 215t, 226

Estrace (micronized 17βE₂), 208, 210, 212t

Estraderm (transdermal 17βE₂), 208, 210, 213t

Estradiol (E₂), 42, 224. See also *Estrogen*; *Estrogen therapy*.

bone mass and, 206, 208

dosage, 210t, 212t-215t, 234-235

endogenous production/level of, 204, 232-234

formulations, 212t-215t

level of

fracture risk and, 204, 205

by menopausal status, 225t

menstrual irregularities and, 61

minimal, to maintain bone mineral density, 204

micronized, 212t, 231

monitoring, 218

osteoblast/osteoclast effects of, 27, 29

transdermal (patch), 210t, 212t-213t

Estrasorb (topical estradiol), 213t

Estratest (esterified estrogens/methyltestosterone), 215t, 226

Estratest HS (esterified estrogens/methyltestosterone), 215t, 226

Estring (estradiol vaginal ring), 213t

Estrogel (transdermal estradiol), 213t

Estrogen, 41-42. See also *Estradiol (E₂)*; *Estrogen therapy*.

action mechanisms, 42-43, 203-204

bioavailability, SHBG and, 41, 204

body fat as source of, 42

bone formation and, 41-42

bone loss and, 149, 152, 204

Estrogen (*continued*)

calcium absorption and, 42, 162, 177
deficiency, 63, 152, 193
 calcium intake needs, 176, 210
 sarcopenia and, 150
estrogen-replete state, 149, 177
exercise and, 27, 153-154
mechanical loading and, 30
osteoblasts/osteoclasts/osteocytes, effects on, 42, 203
receptors (ER α , ER β), 26, 42, 203, 205-206. See also *Selective estrogen receptor modulators*.
 polymorphisms in, bone mass and, 35
 raloxifene binding to, 276
 synthesis and metabolism, 42, 43, 206, 224, 232-234
Estrogen therapy, 202-219. See also *Estrogen*; *Hormone therapy*;
 Selective estrogen receptor modulators; *specific formulations/agents*.
action mechanisms, 203-204
adjustive therapy, 207-211, 209, 210t, 235t
algorithm for, 209
alternative treatments, 216
bone mass and, 206, 208-211, 208, 216
 exercise-plus-estrogen, 153-154
breast cancer and, 229, 230, 232
calcitonin and, 204
cardiovascular disease and, 230-235
combination therapies
 estrogen/androgen, 214t-215t, 222-223, 308-309, 310-312
 with etidronate, 275-276
 with parathyroid hormone, 63, 305, 306-307
 with risedronate, 261-262
dosage, 204-211, 212t-213t
 dose-dependence of effects, 42, 204, 205-207
 to increase bone mass, 210-211
 to maintain bone mass, 208-210, 235t
duration of, 218
effectiveness of, 202-203
in elderly women, 217-218
endometrial hyperplasia induced by, 219, 221, 235
formulations, 212t-215t
fracture prevention with, 202-203, 205
homocysteine level and, 194
indications for, 216-218
lean tissue mass and strength and, 226, 227t
monitoring, 210, 218-219
muscle strength and, 226, 227t
nonresponse to, 211-216
osteoporosis risk and, 68
position statements on use of, 235-236
safety, 219, 229-234
starting, 216-218
Estrone (E $_1$), 42, 207, 224, 232
Estropipate (Ogen, Ortho-Est), 210, 211, 212t

Ethinyl estradiol (FemHRT), 210, 211, 220
Ethinyl estradiol/norethindrone acetate (Femhrt), 215t
Ethnicity. See *Race/ethnicity*.
Etidronate (Didronel), 249, 275-276
 chemical structure, 251
 dosage, 275
 effectiveness, 251
 off label use, 275
European Menopause and Andropause Society, position statement on
 hormone therapy, 236
Evista. See *Raloxifene*.
Exercise, 149-160
 in adolescents/young girls, 21, 37, 151
 age-related sarcopenia and, 149-150
 amenorrhea induced by, 37, 60t, 61-62, 152
 androgen and, 27, 150
 in anorexia patients, 62-63
 bone mass and, 36, 37, 149, 150-152, 153
 bone remodeling and, 37, 125, 150-153
 bone strength and, 21
 calcium and, 153
 estrogen and, 27, 153-154
 excessive, 37, 152-153
 fracture risk reduction with, 153
 mechanical loading in, 150
 muscle-strengthening, 152
 prescription for, 70t, 155-157
 preventive effectiveness of, 149, 153, 158
 repetitions in, 151, 155-156
 stress test for, 157
 supervision in, 155
 in timeline for prevention, 233
 type and frequency of, 37, 150, 155-157
 weight-bearing, 125, 151
 whole body vibration (WBV), 151-152
Falls, 53-57, 134-139
 alcohol intake and, 57
 balance and, 134-139, 149
 direction of, 53, 54-55
 elderly risk for, 53-57
 factors in, 53-57, 75t
 central nervous system disorders, 56-57, 142t
 dizziness, 134-136, 142t
 leg length disparity, 138-139
 medications, 57, 123-124
 muscle mass and strength, 53-56
 soft tissue, 56
 visual impairment, 139, 148
 walking speed, 53-56, 54-55
fractures and, 134-139, 203
 hip fracture, 53-57, 54-56
 vitamin D and, 185, 190t, 191-192

Falls (*continued*)

- prevention of, 57, 158
 - vitamin D and, 185, 190t, 191-192
- Family history. See also *History, patient*.
- bone mass and, 35
 - as osteoporosis risk factor, 59, 60t, 65, 123, 217
 - in patient evaluation, 65, 123
- Fat, body. See *Body fat*.
- Femhrt (ethinyl estradiol/norethindrone acetate), 215t
- Femoral fracture, 105-109. See also *Hip fractures*.
- Femoral neck, 18, 85, 108
- bone composition of, 17
 - bone mass of, alendronate and, 254-255
 - DEXA of, 82-85, 85, 105
 - fracture of, 19, 106
 - length of, 106
 - as predictor of hip fracture, 106-107
- Femoral shaft, 108
- Femring (estradiol vaginal ring), 213t
- Femur. See also *Femoral entries*.
- mechanical strength of, estrogen therapy and, 204
 - neck of. See *Femoral neck*.
 - radiographic measurements, 108
 - shaft of, bone composition, 17, 18
 - width measurements, 106-108, 108
- Finger, bone densitometry of, 88, 89
- Finger-to-nose test, 138
- FIT. See *Fracture Intervention Trial*.
- Fluoride, sodium, 312
- Fluoxymesterone (Halotestin), 214t
- Folic acid, 161, 193, 194
- Follicle-stimulating hormone (FSH), 211, 218
- Forearm, bone densitometry of, 88, 89, 91
- Forteo (teriparatide, recombinant PTH), 39, 302-304
- Fortical. See *Salmon calcitonin*.
- Fosamax. See *Alendronate*.
- Fosamax Actonel Comparison Trials, 253
- Fosamax Plus D. See *Alendronate/cholecalciferol*.
- Fracture Intervention Trial (FIT), 252, 302-304
- Fractures. See also *Hip fractures; Vertebral fractures*.
- average age for, 47
 - bone mass and, 51, 75t
 - cost of, 15
 - in elderly, 53-57, 54-56
 - falls and, 53-57, 54-55, 75t, 185, 191
 - microfractures, 49, 50, 51, 109
 - osteoporotic, factors involved in, 203
 - prediction of, 105-109
 - clinical risk factors and, 68
 - lower extremity length and, 130
 - previous history of, 53, 75t, 101, 102
 - risk of, 13-14, 101, 203, 323
 - antiresorptive agents and, 247-249, 252

Fractures, risk of (*continued*)

- balance and falls and, 134-139, 142t, 149, 203
 - bone marker excretion and, 121
 - bone mass and, 13, 51, 53, 75t, 76-77, 203
 - diabetes and, 326
 - drug use and, 123-124
 - estrogen therapy and, 202-203, 205, 235-236
 - exercise and, 153
 - homocysteine and, 193-194
 - HP/LP ratio and, 32-33
 - lifetime risk, remaining, 47, 75t
 - musculoskeletal system evaluation for, 123-143
 - patient history and, 123-125
 - prevalent/prior fractures and, 53, 101, 102
 - vitamin A and, 194-195
 - vitamin D and, 185, 190t, 191-192
 - vitamin K and, 191, 192
 - sites of, 18, 19
 - stress and, 21, 25
 - trabecular bone, 21-24, 25
 - microfractures, 49, 50, 51
- Fragility of bone, 13-14, 56
- Framingham Osteoporosis Study, 179
- Furosemide, 124
- Gastrectomy, 48, 60t
- Gastrointestinal bypass, 217
- Gastrointestinal side effects, 257, 262
- GE Lunar Achilles, 92
- Gender. See also *Men; Women*.
- bone loss and age and, 19, 22-23
 - hip fracture risk in men, 109
 - osteopenia and, 49
- Genetic factors, peak bone mass and, 35, 36, 59, 60t
- Genetic polymorphisms, 35, 60t
- Genomics, in future identification and prevention, 16, 202
- Geometry of bone, 14, 21
- Geranylgeranylpyrophosphate (GGP), 285
- GIOP (glucocorticoid-induced osteoporosis), 257, 325-326
- GLA-protein. See *Osteocalcin*.
- Glucocorticoids, 40-41. See also *Corticosteroids*.
- bone formation/bone loss and, 40-41
 - long-term therapy, bone mass measurement and, 74t
 - osteoporosis-induced by (GIOP), 325-326
 - alendronate and, 257
 - progesterone and, 43
- Glutamic acid, vitamin K and, 190
- Gluteus maximus, 133, 139
- Gluteus minimus, 133, 140
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 27-29, 28
- Grip-strength, 127, 149, 152, 226
- Growth factors, parathyroid hormone and, 301

Growth hormone, 29, 286
 Gynecologic factors in osteoporosis, 60-62, 60t. See also *Menstruation; Menopause*.
 Gynecologists, in osteoporosis prevention, 16
 Gyno-Sampler endometrial aspirator, 219

HAL (hip axial length), 106
 Halotestin (fluoxymesterone), 214t
 Hamstring muscles, 133, 155, 157
 Hand, grip strength, 127, 149, 152, 226
 Haversian system, 20, 21
 HCTZ (hydrochlorothiazide), decreased hip fracture and, 117
 Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly (HORIZON) Pivotal Fracture Trial, 270-272
 Heart and Estrogen/Progestin Replacement Study (HERS), 201, 230-231
 Heart rate, in exercise program, 157
 Heel. See *Calcaneus*.
 Height, 127-130
 crown to rump, 127-130, 131
 ideal body weight by, 128t-129t
 loss of, 127
 Hematopoiesis, 17
 Heredity, bone mass and, 35, 36, 59, 60t
 HERS (Heart and Estrogen/Progestin Replacement Study), 201, 230-231
 Hip
 bone mass in
 alendronate and, 254-255
 alendronate vs ibandronate, 267
 estrogen/androgen therapy and, 312
 vitamin C and, 193
 DEXA of, 82-85, 85
 fractures of. See *Hip fractures*.
 protectors, 317, 318
 variable bone composition in, 17, 18
 Hip abductor muscles, 133, 140-141
 Hip adductor muscles, 133, 141
 Hip axial length (HAL), 106
 Hip extensor muscles, 133, 139
 Hip flexor muscles, 133, 138
 Hip fractures, 105-109
 average age for, 47, 105
 bisphosphonates and
 alendronate, 251
 risedronate, 252, 259-261, 260
 zoledronic acid, 270-272, 273t
 bone geometry and, 21
 bone loss and, 105
 bone mass and, 53, 105-106
 calcium intake and, 175-176
 DEXA of, 105
 in diagnosis of osteoporosis, 105-109
 in elderly women, 56

Hip fractures (*continued*)
 estrogen therapy and, 202-203, 205
 falls and, 53-56, 54-56
 genesis of, 56
 HCTZ treatment and, 117
 impact of, 315
 predictors of, 105-109
 clinical risk factors, 68
 femoral neck length, 106
 femoral width measurements, 106-109, 108
 lower extremity length, 130
 quantitative ultrasound in, 95-96
 Singh Index, 106, 107
 prevalence of, 315
 prevention of, 21, 317, 318
 proton pump inhibitor therapy and, 175
 senile secondary hyperparathyroidism and, 56
 SHBG and, 207
 sites of, 18
 strontium ranelate and, 287-288
 vitamin A and, 194-195
 vitamin D and, 192
 vitamin K and, 192
 Hip protectors, 317, 318
 History, family. See *Family history*.
 History, patient, 123-125. See also *Family history*.
 calcium intake/absorption, 124
 family history of osteoporosis, 59, 60t, 65, 123
 medications, fracture risk and, 123-125
 menstrual cycle, 61, 123
 risk of falling and fractures, 123-125
 HMG-CoA reductase inhibitors, 285-286
 Hologic Sahara, 92
 Homocysteine, 161, 193-194
 Homocystinuria, 48
 HORIZON trial, 270-272, 271
 Hormonal factors in bone formation/remodeling, 30-31, 38-43
 Hormone therapy, 16, 201-242. See also *Androgen therapy; Estrogen therapy; Progesterone/progestogens*.
 adjustive, 207-211, 209, 210t, 235t
 algorithm for, 209
 androgens, 222-229. See also *Androgen therapy*.
 cardiovascular disease and, 221, 230-235, 233
 caveats in, 202
 clinical studies of, 229-235
 contraindications, 231
 cyclic vs combined, 220-221
 effectiveness of, 235-236
 estrogen, 202-219. See also *Estrogen; Estrogen therapy*.
 estrogen/androgen combinations. See *Androgen therapy; Estrogen therapy*.
 goals of, 202

- Hormone therapy (*continued*)
 individual differences and, 201, 202, 208, 235t
 lipid levels and, 220-221, 229
 monitoring, 235t
 parathyroid hormone combined with, 305, 306-307
 position statements on use of, 235-236
 progesterone/progestogens, 219-222. See also
 Progesterone/progestogens.
 risks of, 229-236
 selectivity in, 201-202
 timing of treatment, 202, 233
- Hormones, age-related decline in, sarcopenia and, 150
- HP/LP ratio, fracture risk and, 32-33
- Human growth hormone (hGH), 29
- Hydrochlorothiazide (HCTZ)
 decreased hip fractures with, 117
 decreased risk of renal stones with, 178
- Hydroxyapatite crystal composition, 161
- Hydroxylysyl-pyridinoline:lysyl-pyridinoline (HP/LP) ratio, 32-33
- Hydroxyproline excretion
 as marker of bone resorption, 117-118, 120t
 vitamin K and, 190
- Hypercalcemia, 276, 281
- Hyperparathyroidism
 as indication for bone mass measurement, 74t
 osteoporosis secondary to, 48, 60t
 secondary, 39
 calcitonin-induced, 284
 glucocorticoids and, 40
 senile secondary, 48, 57
 hip fracture and, 56
 prevention of, 57
- Hyperprolactinemia, 48, 60t, 63
- Hyperthyroidism, 40, 48, 217
- Hyperventilation, 136, 142t
- Hypnotic drugs, 123
- Hypochlorhydria, 174-175
- Hypoestrogenism, 63
- Hypoglycemia, 136, 142t
- Hypogonadism, 48
- Hypotension, orthostatic, 124, 135
- Hypothyroidism, 136, 142t
- Hysterectomy, 60t, 62
- Ibandronate (Boniva), 244t, 263-270
 action mechanisms, 249-250
 chemical structure, 251
 clinical studies, 263-269, 265
 dosage and administration, 244t, 263, 268-270
 effectiveness, 251, 263-269
 bone mineral density, 264-269, 265, 267
 fracture risk reduction, 264, 266
 osteoporosis prevention, 266-268
- Ibandronate (Boniva) (*continued*)
 indications for, 244t, 263-265
 side effects, 244t, 269
 vs alendronate, 266, 267
- Idiopathic osteoporosis, 47, 60t
- Iliac crest, 132, 136
- Iliopsoas muscle, 133, 138
- Imagery, mental, 316
- Immunosuppressive therapy, 327
- Impact of osteoporosis, 15, 315
- Incidence of osteoporosis, 14
- Individual differences, 201, 202, 208, 235t
- Individualized care, 15, 201-202, 309
- Insulin-like growth factor binding proteins (IGFBPs), 41
- Insulin-like growth factors (IGFs), 40, 41
- Integrins, bisphosphonates and, 251
- Interferon, osteoclast inhibition by, 27
- Interleukin-1 (IL-1), osteoclast stimulation by, 27-28
- International Society for Clinical Densitometry, osteoporosis screening
 recommendation, 90-92
- Intestinal bypass, 48, 60t
- Intracortical envelope, 20, 20t
- Intrauterine device (IUD), progesterone-medicated, 222, 235
- Involitional osteoporosis, 47
- Ipriflavone, 286
- Kidney (renal) stones, 176t, 178
- Kyphoplasty, 105, 319, 321
- Kyphosis
 dorsal, 103, 130
 scapula in, 135
 Scheuermann's, 103
- Lactation, 62, 304
- Laxatives, 63
- Lean tissue mass, estrogen/androgen therapy and, 226, 227t
- Leg length disparity
 back pain from, 133, 137
 as clinical sign, 130
 imbalance due to, 138-139
 measurements of, 138-139, 144-145
- Levonorgestrel-containing IUD (Mirena), 222
- Levonorgestrel/estradiol, transdermal (Climara Pro), 215t
- Lifestyle, 59, 125
 in adolescents, 36, 37
 bone mass and, 36, 59, 60t, 324
 as risk factor for osteoporosis, 59, 60t
- Light-headedness, 135-136, 142t
- Lipid levels, hormone therapy and, 220-221, 228-229
- Livial (tibolone), 279-280
- Long bones
 composition of, 17
 ends of, 17, 18, 19
 fractures of, 19

- Lower extremity length, 130
- Lumbar lordosis, 130
- Lumbar spine. See also *Vertebrae*; *Vertebral entries*.
 anatomical landmarks of, 133
 bone mass in
 alendronate vs ibandronate, 267
 alendronate vs risedronate, 254-255
 antiresorptive agents and, 246-247, 246
 estrogen/androgen therapy and, 311
 estrogen therapy and, 204, 206, 208
 parathyroid hormone and, 302-303, 304t
 DEXA of, 80-82, 81
 reference values, 83-84
- Lumbar vertebrae. See *Lumbar spine*.
- Lung cancer, 230
- Lymphotoxin (LT), osteoclast stimulation by, 27
- Macrophage colony-stimulating factor (M-CSF), 27-29, 28
- Magnetic resonance imaging (MRI), 51, 103
- Malabsorption syndromes, 48, 60t, 211, 217
- Mammogram, 219
- Mandibular inferior cortex, 111, 112
- Markers, bone. See *Biochemical markers*.
- Marrow. See *Bone marrow*.
- Matrix proteins. See *Bone matrix*.
- Measurement of bone mass/bone density. See *Bone mass measurement*.
- Mechanical loading, 26-27, 30
 exercise and, 150
 sex steroids and, 30, 42
- Mechanical strength, bone mass and, 51, 52. See also *Bone strength*.
- Medical conditions, secondary osteoporosis from, 48, 60t
- Medically-compromised patients, 324-327
- Medications
 patient history of, 123-124
 risk of falling and, 57, 123-124
 secondary osteoporosis from, 48, 60t, 324
- Medroxyprogesterone acetate (MPA)
 effectiveness, 219-220
 formulations, 213t, 215t
 parathyroid hormone combined with, 305, 306-307
 safety of, 230-231
- Megestrol acetate, 213t
- Men
 bone loss during ageing, 19, 22-23
 hip fracture risk, 109
 osteopenia and trabecular thinning in, 49
 osteoporosis in, 323-324
- Menaquinone (vitamin K₂), 191-192
- Menarche
 late onset
 bone mass and, 37, 38, 60t, 61
 as indication for estrogen therapy, 217
 as starting point for osteoporosis prevention, 149
- Menest (esterified estrogens), 212t
- Menopause. See also *Estrogen therapy*; *Hormone therapy*.
 age at, as screening factor, 64
 androgen/estradiol levels in, 225t
 bone loss after, 60t
 osteoblast and osteoclast activity in, 33
 rate of, 38
 bone mass before, 149
 calcium intake before and after, 162, 163, 173t
 individual differences in, 201, 232
 as normal process of aging, 201
 premature/surgical, 60, 217, 225t
- Menostar (transdermal estradiol), 210, 213t
- Menstruation
 amenorrhea, exercise-induced, 37, 60t, 61-62
 dysfunctional, bone mass and, 37-38, 38, 60t
 history of, 61, 123
 late menarche, 37, 60t, 61
 osteoporosis risk factors, 60-62, 60t
- Methyltestosterone (Android, Testred), 214t, 228-229
 minimal effective dose, 309
- Methyltestosterone/esterified estrogens (Estratest, Estratest HS), 215t, 226
- Mevalonate pathway, bisphosphonates and, 250
- Mevalonic acid, 285
- Miacalcin. See *Salmon calcitonin*.
- Microfractures, 49, 50, 51, 109
 previous, 101, 102, 105
- Mineralization. See *Bone mineralization*.
- Mirena (levonorgestrel-containing IUD), 222
- MOBILE (Monthly Oral Ibandronate in Ladies) study, 264-265, 265
- Monthly Oral Ibandronate in Ladies (MOBILE) study, 264-265, 265
- Monthly Oral Therapy with Ibandronate for Osteoporosis iNtervention (MOTION) trial, 266
- MORE (Multiple Outcomes of Raloxifene Evaluation), 278
- MOTION (Monthly Oral Therapy with Ibandronate for Osteoporosis iNtervention) trial, 266
- MPA (medroxyprogesterone acetate)
 effectiveness, 219-220
 formulations, 213t, 215t
 parathyroid hormone combined with, 305, 306-307
 safety of, 230-231
- MTHFR gene, 193
- Multiple myeloma. See *Myeloma, multiple*.
- Multiple Outcomes of Raloxifene Evaluation (MORE), 278
- Muscle mass
 age-related loss of, 149-150
 androgens and, 226
 determination of, 127
 exercise and, 150, 152
 vitamin D and, 179
- Muscle spasm, paravertebral, 132, 136

- Muscle strength, 130-134
 age-related decrease in, 149-150
 androgen therapy and, 226, 227t
 back pain and, 130-134, 134-136
 bone mass and, 190t
 in elderly persons, 53-56, 226
 estrogen therapy and, 226, 227t
 evaluation of, 130-134
 exercise and, 150, 152
 exercises for, 316
 testing for, 138-141
 vitamin D and, 179, 185, 191
 whole body vibration and, 152
- Musculoskeletal system, evaluation of. *See Clinical evaluation.*
- Myeloma, multiple, 48, 60t
 screening for (with sedimentation rate), 111
 zoledronic acid for, 270
- Myocardial infarction, 230, 233
- N-carboxytelopeptide (NTx), 118-119, 121
- National Osteoporosis Foundation (NOF)
 osteoporosis screening recommendation, 90
 prevention and treatment recommendations, 70t-71t
- National Osteoporosis Risk Assessment Study, 65, 87
- NETA (norethindrone acetate), 213t, 219-221, 231
- Nitric oxide (NO), 26, 30
- NOF. *See National Osteoporosis Foundation.*
- Nondrug therapy, 315-322
 hip protectors, 317, 318
 physical therapy, 315-317
 surgical interventions, 319
 vertebral stabilization, 317-319, 320-321
- Nonpharmacologic interventions, recommended regimens, 70t-71t
- Nor-QD (norethindrone), 213t
- NORA. *See National Osteoporosis Risk Assessment Study.*
- Norethindrone (Ortho Micronor, Nor-QD), 213t
- Norethindrone acetate (NETA, Aygestin), 213t, 219-221, 231
- Norethindrone acetate/ethinyl estradiol (Femhr), 215t
- Norethindrone acetate/estradiol (Activella), 214t, 220
- Norethindrone acetate/estradiol (CombiPatch), 215t
- Norgestimate/estradiol (Prefest), 215t
- Norgestrel, 274
 levonorgestrel, 215t, 222
- North American Menopause Society
 consensus opinion on calcium, 177
 position statement on estrogen and progestogen use, 235-236
- NTx (N-carboxytelopeptide), 118-119, 121
- Nurses Health Study, retinol in, 195
- Nutrition, 36-37, 149
 in adolescents, 37
 bone mass and, 36-37, 36, 59, 60t
 calcium and vitamins D, K, C, and A, 161-200
 in prevention, 16, 233
- Nutritionists, in osteoporosis prevention, 16
- Nystagmus, 135, 136, 142t
- Obesity. *See also Body weight.*
 definition of, 125
 reduced fracture risk with, 56
 reduced osteoporosis risk with, 42, 68, 127
- Ogen (estropipate), 210, 211, 212t
- Oligohypomenorrhea, 60t
- Oligomenorrhea, 61-62, 217
- Oral contraceptive use, 38, 217. *See also Estrogen therapy; Hormone therapy.*
 in osteopenia screening, 64
 as preventive therapy, 92
- Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE), 263-264
- Ortho-Est (estropipate), 212t
- Ortho Micronor (norethindrone), 213t
- Orthostatic hypotension, 124, 135, 136
- OsCal (calcium carbonate), 180t
- Osteoarthritis, of vertebral disks, 104-105
- Osteoblasts, 26
 androgens and, 206, 223, 309
 bone formation biomarkers of, 115-117
 in bone remodeling, 30, 32, 33, 34
 estrogen/androgen receptors in, 26, 206
 estrogen effects on, 26, 42
 functions of, 26
 glucocorticoids and, 40
 impaired, bone loss and, 33
 in mechanical loading, 30
 parathyroid hormone and, 29, 39, 301
 progesterone receptors in, 43
 stimulators and inhibitors of, 29
 trabecular thinning and, 94
 vitamin C and, 193
 vitamin D and, 29, 40, 183
- Osteocalcin (bone GLA-protein, BGP)
 in bone formation, 32, 116, 120t
 circadian secretion of, 116
 vitamin K and, 190
- Osteoclasts, 24-26
 androgen/estrogen receptors in, 26, 223
 in bone loss, 33, 49
 in bone remodeling, 24-26, 33, 34
 calcitonin and, 281
 chemotaxis of, vitamin K and, 190
 estrogen effects on, 27, 42, 203
 factors controlling, 24-26, 27. *See also Antiresorptive agents.*
 calcitonin, 27, 40
 stimulators and inhibitors of, 27-28
 functions of, 24

- Osteoclasts (*continued*)
 in mechanical loading, 30
 overactive, 33
 parathyroid hormone and, 27, 39, 301
 precursor/stem cells, 27-29, 28, 30
 trabecular network erosion from, 49
 vitamin C and, 193
 vitamin D and, 40
- Osteocytes, 26-27
 androgen/estrogen receptors in, 26, 223
 estrogen effects on, 42
 mechanical loading and, 26-27, 30, 42
- Osteogenesis imperfecta, 48
- Osteoid, 31, 32-33, 115, 149, 203. See also *Bone formation*.
- Osteomalacia
 testing for, 111
 vitamin D deficiency and, 33, 40
- Osteomark-NTX (N-telopeptide), 121, 218
- Osteonecrosis of the jaw (ONJ), bisphosphonates and, 275-276
- Osteonectin, 32, 116-117
- Osteopenia, 14, 49, 50-53, 52
 adjustive hormone therapy for, 207-211, 209, 235t
 age-related sarcopenia and, 150
 androgens in therapy for, 235t
 in children, 324
 definition of, 14, 324
 degree of, bone mass and, 14, 76, 77t
 exercise-induced, 152-153
 gender and, 49
 gynecologic factors in, 60-62, 60t
 measures of, 74-76
 osteoporosis vs, 14, 119-121
 as precondition to osteoporosis, 15, 50-53
 reversibility of, 49, 52, 101
 as risk factor for osteoporosis, 14, 53. See also *Risk factors for osteoporosis*.
 screening for, 64-68, 87-89, 89
 perimenopausal, 15
 site of, variability in, 87
 timeline of prevention and intervention, 233
 trabecular architecture in, 25, 49, 50
- Osteoporosis
 characteristics of, 13-14
 definition of, 14, 77, 324
 distinguished from osteopenia, 14, 119-121
 high-turnover vs low-turnover, 301, 302, 309
 impact of, 15, 315
 primary vs secondary, 47-48, 323
 timeline of prevention and intervention, 233
 trabecular architecture in, 25
- Osteoprotegerin, 26, 29
- Osteosarcoma, parathyroid hormone and, 304
- Ovaries
 normal function, in bone accrual, 36, 149
 oophorectomized women, 43
 premature ovarian failure, 63
- Paget's disease
 bisphosphonates for, 274-275
 salmon calcitonin for, 281, 283
- Pain
 causes of, 130-133, 134-137
 evaluating, 130-133
 impact of, 315
 relief measures for, 105, 132, 315-322
 of spinal fractures, 105, 123
- Pamidronate, 249, 275
- Parathyroid adenoma, 39
- Parathyroid hormone (PTH), 39, 301-308. See also *Hyperparathyroidism*.
 action mechanism, 39, 301
 ageing and, 57
 anabolic effect, biologic basis for, 301-302
 for anorexia patients, 63
 antiresorptive maintenance after, 305, 307
 bone formation and, 39
 bone loss and, 301
 bone mass and, 39
 bone turnover and, 39
 chemical structure, 301-302
 clinical trials, 302-305, 303, 304t
 in combination with hormone therapy, 305, 306-307
 contraindications, 304
 cyclic adenosine monophosphate (cAMP) and, 26
 dosage, formulations, and use, 302-305, 306-307
 effectiveness, 302-305
 bone mineral density, 302-304, 304t, 305, 306-307
 fracture risk reduction, 302-304, 303, 305
 estrogen and, 42, 204
 excessive, 39
 indications for, 301
 long-term treatment, 304
 osteoblasts and osteoclasts, effects on, 29, 39, 301
 in osteoporosis diagnosis, 111
 side effects, 304
 trabecular connectivity and, 39, 49, 305-308, 308
 vitamin D and, 183, 190t
- Paravertebral muscle spasm, 132, 136
- Pathogenesis of osteoporosis, 48-58
 in cortical bone, 49-50
 main factors in, 48-57
 falls, 53-57, 54-55
 microarchitecture and bone repair, 49-50, 50
 reduced bone mass/osteopenia, 50-53, 52
 reversible vs irreversible changes in, 49, 52

Pathogenesis of osteoporosis (*continued*)
 senile secondary hyperparathyroidism in, 48, 57
 theoretical effects of treatment, 52, 53
 in trabecular bone, 49, 50, 52
Patient compliance. See *Compliance, patient*.
Patient education, about bone mass/bone loss, 13
Patient evaluation. See *Clinical evaluation*.
Pelvic tilt/rotation, 130, 133, 133, 137
Pelvis
 radiographic measurements, 108
 radiographs, role in diagnosis, 109
Percutaneous vertebral augmentation, 105
Periosteal envelope, 20, 20
Peripheral quantitative computed tomography (pQCT), 24
PGE₂. See *Prostaglandins*.
Pharmacists, in osteoporosis prevention, 16
Phenotype, small-boned, 60t
Phosphorus
 as bone component, 161
 calcium-to-phosphorus ratio, 178-179, 184t-185t
 excess, 178-179
 food sources of, 178, 184t-185t
Physical therapy, 16, 133, 315-317
Phytonadione (vitamin K₁), 191
Pipelle endometrial aspirator, 219
Plasma tartrate-resistance acid phosphatase, 120t
Polymorphisms, 35, 60t
Posture (calcium phosphate), 180t
Posture, back pain and, 130, 315-316
PPIs (proton pump inhibitors), calcium absorption and, 174-175
pQCT (peripheral quantitative computed tomography), 24
Prefest (norgestimate/estradiol), 215t
Pregnancy
 PTH contraindication in, 304
 zoledronic acid contraindication in, 274
Premarin. See *Conjugated equine estrogen (CEE, Premarin)*.
Premphase (conjugated estrogens/MPA), 215t
Prempro (conjugated estrogens/MPA), 215t, 230-231
Preos (recombinant human PTH), 305. See also *Parathyroid hormone*.
Prevention of osteoporosis, 13, 14-16, 70t-71t
 age-related steps in, 15
 calcium intake and, 175-178
 genomic medicine and, 16, 202
 hormonal therapy in, 202
 identification of patients at risk, 309
 nondrug therapy in, 315-317
 post-event prevention, 13, 202, 233
 primary prevention, 13, 202, 233
 pyramid approach to, 70t-71t
 recommended regimens, 70t-71t
 secondary prevention, 13, 202, 233
 strategies in, 16

Prevention of osteoporosis (*continued*)
 timeline of opportunity, 233
 vs treatment, 202
Primary-care physicians, in osteoporosis prevention and treatment, 13, 15, 16
Primary osteoporosis, 47, 60t
Procollagen I extension peptides, 116, 120t
Progesterone/progestogens, 43, 219-222. See also *Estrogen therapy; Hormone therapy*.
 cyclic vs continuous combined therapy, 220-221
 effectiveness, 219-220
 effects of, 219
 endometrial protective effect, 219
 estrogen/progestogen combinations, 214t-215t
 formulations, 213t-215t, 219-220
 medicated IUDs, 222, 235
 type and dose, 219-220
 indications for, 221-222
 micronized, 214t, 220, 228, 235
 position statements on use of, 235-236
 receptors, 219
 estrogen effect on, 26, 43, 203, 221
 regimens, 221
 safety, 222
 side effects, 220-221, 222
Progesterin, 209, 216, 235
Prometrium (micronized oral progesterone), 214t, 220
PROOF study, 282
Prostaglandins
 bone remodeling and, 30
 osteoblast stimulation by, 29
 osteocyte production of, 26
Protelos. See *Strontium ranelate*.
Proton pump inhibitors (PPIs)
 calcium absorption and, 174-175
 increased fracture risk and, 325
Provera (medroxyprogesterone acetate), 213t
Psychotropic drugs, 123
PTH. See *Parathyroid hormone*.
Pulmonary embolism, raloxifene and, 278
Pyramid Approach to prevention and treatment, 70t-71t
Pyridinoline (Pyr), 118, 120t
Pyrilinks-D, 121, 218

Quadriceps, 152, 155, 157
Quality of life, impact of osteoporosis on, 15, 315
Quantitative bone ultrasound (QUS), 92-96
Quantitative computed tomography (QCT), 79t, 80, 103
Quantitative sound index (QUI), 94

Race/ethnicity
 bone mass and, 35
 DEXA reference values, 86

Race/ethnicity (*continued*)

- osteoporosis incidence and, 14
- osteoporosis risk and, 59, 60t, 68

Radiographic absorptiometry. See *Dual-energy x-ray absorptiometry*;
Single x-ray absorptiometry.

Radius

- bone mass in, vitamin C and, 193
- distal, bone composition in, 17, 18
- distal, bone densitometry of, 87, 88, 91
- magnetic resonance imaging with DTA, 109-110, 110
- midshaft, bone composition in, 17

Raloxifene (Evista)

- dosage, 245t, 278-279
- effectiveness, 245t, 277-278
- indications for, 244t, 277
- side effects, 245t, 278
- systemic effects, 276-277
- vertebral fracture prevention with, 53

Rancho Bernado study, 195

RANK-RANKL

- bisphosphonates and, 251
- monoclonal antibody to (denosumab), 247, 288-289
- osteoblast activity and, 26, 28
- parathyroid hormone and, 301

Reclast. See *Zoledronic acid*.

Remodeling of bone. See *Bone remodeling*.

Renal failure, 48, 60t

Renal stones, calcium intake and, 176t, 178

Resorption. See *Bone resorption*.

Retinoic acid, 194

Retinol. See *Vitamin A*.

Rheumatoid arthritis, 48

Rhomboid muscle, back pain and, 132, 135

Risedronate (Actonel), 244t, 258-263

- action mechanisms, 249-250
- chemical structure, 251
- clinical trials, 258-259
- in combination with estrogen therapy, 261-262
- dosage, 244t, 261, 262-263
- effectiveness, 251, 258-261, 260
 - bone mineral density, 253, 254-255, 259, 261-262
 - in corticosteroid therapy and chemotherapy, 261
 - fracture risk reduction, 244t, 252, 259-261, 260
 - vs alendronate, 253, 254-255
- indications for, 244t, 258
- in older women, 259-261, 260
- side effects, 244t, 262

Risedronate/calcium carbonate (Actonel with Calcium), 244t, 263

Risk factors for osteoporosis, 13, 59-72, 60t. See also *Menopause*;

- Pathogenesis of osteoporosis; specific risk factors*.
- characteristics of women at risk, 60t
- clinical determination of risk, 309-313

Risk factors for osteoporosis (*continued*)

- clinical risk factors (CRF), 68
 - in detection of osteoporosis, 64-68
 - eating disorders, 62-63
 - endocrinopathies, 60t, 63
 - ethnicity/race, 59, 60t, 68
 - in fracture prediction, 68
 - gynecologic factors in, 60-62, 60t
 - high-risk individuals, 95t, 217
 - lifestyle, 59, 60t
 - questionnaire for, 65, 66-67, 68
 - scoliosis, 63-64
 - screening for, 64-68
 - screening recommendations based on, 90-92, 93t-95t
 - selectivity in hormonal therapy and, 201-202
- Romberg's maneuver, 138
- Rotterdam study, risk factors in, 194

Sacroiliac joint, 133, 137

Salmon calcitonin (Miacalcin, Fortical), 245t, 281-285. See also *Calcitonin*.

available preparations, 245t, 281-283

in clinical practice, 283

dosage, 245t, 282-283

effectiveness, 245t, 281-283

indications for, 245t, 281, 282, 283, 284

long-term compliance with, 285

for Paget's disease, 281, 283

precautions, 284

regimens, 283-284

side effects, 245t, 284

Sarcopenia, age-related, 149-150

vitamin K and, 191

Scapula

back pain and, 130-132, 134-135, 316

in kyphosis, 134-135

normal position of, 132, 135

stabilization of, 316

Scheuermann's kyphosis, 103

Scoliosis, 63-64

back pain in, 132

bone mass/osteoporosis risk and, 60t, 63-64

prevalence of, 63

in skeletal evaluation, 130

Screening, 64-68

for osteopenia, 64-68, 87-89, 89

cost-effectiveness of, 15-16

in perimenopausal women, 15-16

risk factor use in, 64-68

for osteoporosis, 87-92, 93t-95t

age at, 90-92

baseline BMD, 92

risk factor use in, 64-68

screening tool, author's, 88, 89

- Screening (*continued*)
- patient self-evaluation form, 66-67, 68
 - recommendations for, 90-92, 93t-95t
 - risk-factor questionnaire, 65, 66-67
 - T scores in, 70t-71t
- Secondary osteoporosis, 47-48, 323
- causes of, 48, 60t, 323
 - evaluating, 111
 - incidence of, 47
- Sedimentation rate, in screening for multiple myeloma, 111
- Selective estrogen receptor modulators (SERMS), 243, 245t, 276-280.
- See also *Raloxifene*.
- Selective serotonin reuptake inhibitors (SSRIs), 325
- Senile secondary hyperparathyroidism, 48, 57
- hip fracture and, 56
- Sequential Multiple Analysis-25 (SMA-25), 121
- SERMS. See *Selective estrogen receptor modulators*.
- Sex hormone-binding globulin (SHBG), 41, 204
- bone formation and, 41
 - estrogen/androgen therapy and, 226, 231, 309
 - estrogen bioavailability and, 41, 204
 - fracture risk and, 204-205, 207
- Sex hormones. See also *Androgens; Estrogen*.
- mechanical loading and, 30
- SHBG. See *Sex hormone-binding globulin (SHBG)*.
- Shoulder height, 130, 132
- Sialoprotein II, 116-117
- Singh index, 106, 107
- Single photon absorptiometry (SPA), 87, 88
- Single x-ray absorptiometry (SXA), 79t, 88
- accuracy and precision of, 79t, 88, 90
 - cost of, 79t
 - of forearm/hand/heel, 88
 - in osteopenia-identification program, 89
 - radiation dose, 79t
- Skeletal frame size, 125-127
- determination of, 127, 130t
 - ideal body weight, by height and, 126t
- Skeleton, 17-19, 18, 127-130. See also *Bone entries*.
- bony landmarks of, 132-133
 - evaluation of, 127-130, 131
 - functions of, 17
- Skin, vitamin D synthesis and, 179, 188
- Skinfold thickness, 125-127
- Smoking
- bone loss and, 59
 - in osteopenia screening, 64, 65
 - as osteoporosis risk factor, 59, 65
- Sodium
- as constituent of bone, 161
 - low-sodium diets, 176t
- Sodium fluoride, 312
- Soft tissue, 56
- SOTI trial, 287
- Sound, speed through bone, 94, 96
- SPA (single photon absorptiometry), 87
- Special populations, osteoporosis in, 323-329
- children, 324
 - medically-compromised patients, 324-327
 - men, 323-324
- Speed of sound (SOS) through bone, 94, 96
- Spinal fracture. See *Vertebral fractures*.
- Spinal Osteoporosis Therapeutic Intervention (SOTI) trial, 287
- Spine. See also *Vertebrae; Vertebral entries*.
- densitometry of, 80-82, 81, 83-84
 - kyphoplasty, 105, 319, 321
 - surgical treatment, 319
 - vertebral stabilization, 317-319, 320-321
- SSRIs, bone metabolism and, 325
- Standard deviation (SD), in bone mass measurement, 74-77, 77t
- Statins, 285-286
- Stature. See *Height*.
- Steroids. See *Androgens; Estrogen; Hormone therapy*.
- Stiffness of bone, 94
- Stress fractures, trabecular bone strength and, 21, 25
- Stress test, exercise, 157
- Strontium ranelate (Protelos), 286, 287-288
- Surgeon General, US, Pyramid Approach to prevention and treatment, 70t-71t
- Surgical treatment of osteoporotic spine, 319
- Syncope, 135, 142t
- T-score, 76, 85
- treatment recommendations based on, 70t-71t
 - variation in different skeletal sites, 87
- Tamoxifen, 279
- Tensile strength of bone, 32
- Teriparatide (recombinant human PTH, Forteo), 39, 302-304. See also *Parathyroid hormone*.
- Testosterone, 223, 224. See also *Androgen therapy*.
- conversion to estrogens, 42, 223, 224
 - decline in, sarcopenia and, 150
 - formulations, 214t, 226-228
 - combination formulations, 215t
 - patch, 228
 - pellets, 226
 - level in women, by menopausal status, 225t
 - receptors, 223
- Testosterone enanthate (Delatestryl), 214t, 228
- Testosterone propionate, 228
- Testred (methyltestosterone), 214t
- TGF (transforming growth factor), 27, 29
- Therapeutic triangle, 149
- Thiazide diuretics, 124, 287
- Thoracic vertebrae, 132. See also *Vertebrae*.

- Thromboembolic disease, raloxifene and, 278
- Thyroid hormones, 40. See also *Parathyroid hormone*.
 bone formation and, 40
 bone remodeling and, 124
 hyperthyroidism, 40, 48, 217
 osteoblast stimulation by, 29
 in osteoporosis diagnosis, 111
 therapy with
 estrogen therapy and, 217
 monitoring/reassessment, 40, 124
 secondary osteoporosis from, 48, 60t
- Tibia, quantitative ultrasound of, 94-96
- Tibolone (Livial), 279-280
- Tiludronate, 275
- TOP study, 305
- Torsional bone strength index (BSIt), 24
- Trabecular bone, 21-24
 anatomy of, 21, 25
 architecture in normal vs reduced bone states, 25, 52
 in distal radius, 17
 during puberty, 61
 exercise and, 153
 fractures, 14, 19, 21, 25
 microfractures, 49, 50
 prevention of, 21-24
 in hip, 106, 107
 loss of, 19, 19, 38, 49
 rate of, 38
 microarchitecture, 49, 50
 antiresorptive agents and, 247, 248
 digital topologic analysis of, 109-110, 110, 311
 parathyroid hormone and, 39, 49, 305-308, 308
 reversibility of damage to, 307-308, 308, 311
 microfractures, 49, 50, 51, 109
 network of, DTA imaging of, 109-110, 110
 in osteopenia, 25, 49, 50
 in osteoporosis, 47, 49, 50
 plates of, 25, 49, 50
 connectivity, parathyroid hormone and, 39, 49, 305-308, 308
 fractures and, 14, 19, 24, 25, 49, 50
 integrity of, early interventions and, 21-24
 mechanical strength and, 51, 52
 remodeling, 17, 21, 25
 thinning and damage, 49, 50
- Transdermal estrogen agents, 212t-213t
- Transforming growth factor- α (TGF- α), 27
- Transforming growth factor- β (TGF- β), 27, 29
- Transplant recipients, osteoporosis and, 326-327
- Treatment of osteoporosis. See also *Prevention of osteoporosis; specific therapies*.
 antiresorptive agents, 243-300
 bone formation stimulators, 301-314
 Treatment of osteoporosis (*continued*)
 bone mass measurement in assessment of, 74t
 calcium and vitamins, 161-200
 costs/cost-effectiveness of, 15
 exercise, 149-160
 hormone therapy, 201-242
 nondrug therapy, 315-322
 recommended regimens, 70t-71t
 therapeutic triangle, 149
 timeline of opportunity, 233
 treating the individual, 15, 201-202, 309
 Treatment of Osteoporosis with PTH (TOP) study, 305
 Treatment Of Peripheral Osteoporosis (TROPOS) trial, 287-288
 Triceps, 155
 Tricyclic antidepressants, 123-124
 Trochanter, 18, 85
 alendronate and, 254-255
 bone composition of, 17
 interpreting DEXA of, 105, 107
 radiographic measurements of, 108
 TROPOS trial, 287-288
 Tumor necrosis factor (TNF), 27-28
 Tums (calcium carbonate), 180t
 Turner's syndrome, 60t, 63
 Twins, bone mass in, 59
 Type I vs Type II primary osteoporosis, 47
- Ulna, bone densitometry of, 88
 Ultrasound critical angle reflectometry (UCR), 95
 Ultrasound, quantitative (QUS), 92-96
 Uncoupling, in bone remodeling, 33, 47
 Upper back pain, 130-132, 134-135
 Urinary calcium excretion, 117
 Urinary hydroxylysine glycosides, 120t
 Urinary hydroxyproline, 117-118, 120t
 US Preventive Services Task Force (USPSTF), screening
 recommendation, 90
 US Surgeon General, Pyramid Approach to prevention and treatment, 70t-71t
 UV-B irradiation, vitamin D and, 179, 188
- Vasovagal attacks, 135, 142t
 VDR. See *Vitamin D, receptor (VDR)*.
 Vegan diet, calcium intake needs, 176t
 Vegetarian diet, calcium intake needs, 176t
 Vertebrae, 18. See also *Lumbar spine; Vertebral entries*.
 bone density peak, 38
 bone mass of
 exercise plus estrogen therapy and, 154
 peak, age at, 38
 compressive strength of, age and, 25
 lumbar, anatomical landmarks of, 133
 paravertebral muscle spasm, 132, 136

Vertebrae (*continued*)

- stabilization of, 317-319, 320-321
- upper thoracic, anatomical landmarks of, 132

Vertebral deformity

- degrees of, 101, 104
- as indication for bone mass measurement, 74t

Vertebral disk degeneration and osteoarthritis, 104-105

Vertebral fractures, 101-105

- average age for, 47
- bisphosphonates and
 - alendronate, 251, 255
 - ibandronate, 264, 266
 - risedronate, 252, 255, 259
 - zoledronic acid, 270, 271, 273t
- classification of, 101-103, 104
- deformation degrees, 101-103, 104
- DEXA of, 103-104, 105
- in diagnosis of osteoporosis, 101-105
- eating disorders and, 62
- estrogen therapy and, 202-203, 205
- falls/trauma and, 53
- incidence of, 19
- magnetic resonance imaging for, 103
- pain and disfigurement of, 123, 315
- pain relief techniques, 317-319
 - kyphoplasty, 105, 319, 321
 - percutaneous vertebral augmentation, 105
 - vertebroplasty, 105, 318-319, 320
- parathyroid hormone and, 302-304, 303, 305
- previous microfractures, 101, 102, 105
- quantitative computed tomography for, 103
- raloxifene and, 53, 278
- risk of
 - prevalent fractures and, 101, 102
 - vitamin K and, 191
- SHBG and, 207
- strontium ranelate and, 287-288
- x-rays of, 101, 103-105

Vertebral stabilization, 317-319, 320-321

Vertebroplasty, 105, 318-319, 320

Vertigo, 56, 135, 142t

Vestibular dysfunction, 135, 142t

Viaactiv (calcium carbonate), 180t

Virilon (methyltestosterone), 214t

Visual contrast sensitivity, 139, 148

Visual impairment, falls and fractures and, 139, 148

Vitamin A (retinol), 194-195

Vitamin B₆ and B₁₂, homocysteine and, 193, 194

Vitamin C, 193-194

Vitamin D, 39-40, 124, 179-185. See also *Calcium*.

- action mechanisms, 39-40, 179, 186
- active form (1,25(OH)₂D), 179, 187-189

Vitamin D (*continued*)

- analogs, 286
 - assessment, 183
 - bone formation and, 33, 39-40
 - bone loss and, 183, 190t
 - bone mass and, 35, 37
 - bone mineralization and, 33
 - calcium absorption and, 57, 177, 179
 - cholecalciferol (vitamin D₃), 181t
 - with alendronate (Fosamax Plus D), 244t, 258
 - deficiency, 40, 57, 191
 - calcitonin-induced, 284
 - osteomalacia and, 33, 40
 - PTH and bone remodeling in, 39
 - as risk factor for osteoporosis, 59
 - sarcopenia and, 150
 - senile secondary hyperparathyroidism and, 57
 - dosage
 - glucocorticoid use and, 41
 - optimal levels, 183, 190t, 194
 - recommended daily intake, 70t, 181t, 190t
 - factors influencing, 183
 - seasonal adjustments in, 37, 183
 - estrogen activation of, 42
 - excessive, 60t
 - fall/fracture risk and, 185, 191-192
 - intake
 - age/seasonal/lifestyle adjustments in, 37, 125
 - assessment form, 173t
 - optimal daily dose, 194
 - recommended daily dose, 70t, 181t, 190t
 - as screening factor, 64
 - muscle strength and, 179, 185, 191
 - osteoblast and osteoclast effects of, 29, 40
 - parathyroid hormone and, 183, 190t
 - receptor (VDR), 179, 183, 186, 189
 - sites of action, 39-40, 179, 188-189
 - sources and function, 179-183, 188-189
 - supplementation
 - in elderly, 124, 185, 191
 - formulations and recommended dose, 181t-182t, 183, 190t, 194
 - for senile secondary hyperparathyroidism, 57
 - target organs for, 179, 188-189
 - vitamin A relationship with, 194
- Vitamin K, 190-193, 286
- effects of, 190
 - fracture risk and, 192
 - sources of, 191-192
- Vivelle (transdermal estradiol), 208, 213t

Walk Tall. An Exercise Program for the Prevention and Treatment of Osteoporosis (Meeks), 315

Walking
 back pain and, 316
 speed, fall direction and, 53, 54-55
 tests for disequilibrium, 138
Ward's triangle, DEXA of, 82-85, 85, 105
Wedge deformity, 101, 104
Weight. See *Body weight; Eating disorders; Obesity*.
WHI. See *Women's Health Initiative (WHI)*.
Whole body vibration (WBV), 151-152
Women. See also *Gender; Menopause; Menstruation*.
 bone loss during ageing, 19, 22-23
 bone resorption after menopause, 49
 elderly, hip fracture genesis, 56
 incidence of osteoporosis, 14
 at risk for osteoporosis, identifying. See *Risk factors for osteoporosis*.
Women's Health Initiative (WHI), 231-234
 breast cancer risk in, 229, 232
 calcium supplementation in, 177-178
 cardiovascular disease in, 229, 232
 flaws in, 232
 fracture risk on estrogen therapy, 202-203
 goals of, 231-232
World Health Organization, definition of osteoporosis, 77
Wrist, bone densitometry of, 88
Wrist fractures, 18
 alendronate and, 252
 strontium ranelate and, 287

Z-score, 74-76
Zinc deficiency, 153
Zoledronic acid (Reclast), 245t, 270-274
 clinical trials, 270-272, 271
 dosage and administration, 245t, 274
 effectiveness, 245t, 270-272, 271, 273t
 indications for, 245t, 270
 side effects, 245t, 272-274
Zometa, contraindication for Reclast, 274